###begin article-title 0
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vascular</italic>
###xml 81 106 81 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">endothelial growth factor</italic>
A Novel Tumor-Promoting Function Residing in the 5' Non-coding Region of vascularendothelial growth factor mRNA
###end article-title 0
###begin article-title 1
Regulatory RNAs: Have mRNA Untranslated Regions Joined the Party?
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 222 225 222 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 303 306 303 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 385 388 385 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 494 498 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1653 1657 1649 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 212 217 <span type="species:ncbi:9606">human</span>
###xml 1056 1065 <span type="species:ncbi:10090">nude mice</span>
Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 5'UTRs. Using these plasmids, we revealed that the 5'UTR of vegf mRNA possessed anti-apoptotic activity. The 5'UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 5'UTR or the mutated 5'UTR. The clones expressing the 5'UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 5'UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 5'UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)alpha therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNalpha responses.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.
###end p 7
###begin p 8
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Shigetada Teshima-Kondo and colleagues find that cancer cells have a survival system that is regulated by vegf mRNA and that vegf mRNA and its protein may synergistically promote the malignancy of tumor cells.
###end p 8
###begin title 9
Editors' Summary
###end title 9
###begin title 10
Background
###end title 10
###begin p 11
Normally, throughout life, cell division (which produces new cells) and cell death are carefully balanced to keep the body in good working order. But sometimes cells acquire changes (mutations) in their genetic material that allow them to divide uncontrollably to form cancers-disorganized masses of cells. When a cancer is small, it uses the body's existing blood supply to get the oxygen and nutrients it needs for its growth and survival. But, when it gets bigger, it has to develop its own blood supply. This process is called angiogenesis. It involves the release by the cancer cells of proteins called growth factors that bind to other proteins (receptors) on the surface of endothelial cells (the cells lining blood vessels). The receptors then send signals into the endothelial cells that tell them to make new blood vessels. One important angiogenic growth factor is "vascular endothelial growth factor" (VEGF). Tumors that make large amounts of VEGF tend to be more abnormal and more aggressive than those that make less VEGF. In addition, high levels of VEGF in the blood are often associated with poor responses to chemotherapy, drug regimens designed to kill cancer cells.
###end p 11
###begin title 12
Why Was This Study Done?
###end title 12
###begin p 13
###xml 525 529 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 633 637 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 847 851 847 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
Because VEGF is a key regulator of tumor development, several anti-VEGF therapies-drugs that target VEGF and its receptors-have been developed. These therapies strongly suppress the growth of tumor cells in the laboratory and in animals but, when used alone, are no better at increasing the survival times of patients with cancer than standard chemotherapy. Scientists are now looking for an explanation for this disappointing result. Like all proteins, cells make VEGF by "transcribing" its DNA blueprint into an mRNA copy (vegf mRNA), the coding region of which is "translated" into the VEGF protein. Other, "noncoding" regions of vegf mRNA control when and where VEGF is made. Scientists have recently discovered that the noncoding regions of some mRNAs suppress tumor development. In this study, therefore, the researchers investigate whether vegf mRNA has an unrecognized function in tumor cells that could explain the disappointing clinical results of anti-VEGF therapeutics.
###end p 13
###begin title 14
What Did the Researchers Do and Find?
###end title 14
###begin p 15
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 569 573 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 907 911 907 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1304 1308 1304 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 991 996 <span type="species:ncbi:9606">human</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
The researchers first used a technique called small interfering (si) RNA knockdown to stop VEGF expression in human colon cancer cells growing in dishes. siRNAs are short RNAs that bind to and destroy specific mRNAs in cells, thereby preventing the translation of those mRNAs into proteins. The treatment of human colon cancer cells with vegf-targeting siRNAs made the cells more sensitive to chemotherapy-induced apoptosis (a type of cell death). This sensitivity was only partly reversed by adding VEGF to the cells. By contrast, cancer cells engineered to make more vegf mRNA had increased resistance to chemotherapy-induced apoptosis. Treatment of these cells with an antibody that inhibited VEGF function did not completely block this resistance. Together, these results suggest that both vegf mRNA and VEGF protein have anti-apoptotic effects. The researchers show that the anti-apoptotic activity of vegf mRNA requires a noncoding part of the mRNA called the 5' UTR, and that whereas human colon cancer cells expressing this 5' UTR form tumors in mice, cells expressing a mutated 5' UTR do not. Finally, they report that the expression of several pro-apoptotic genes and of an anti-tumor pathway known as the interferon/STAT1 tumor suppression pathway is down-regulated in tumors that express the vegf 5' UTR.
###end p 15
###begin title 16
What Do These Findings Mean?
###end title 16
###begin p 17
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
These findings suggest that some cancer cells have a survival system that is regulated by vegf mRNA and are the first to show that a 5'UTR of mRNA can promote tumor growth. They indicate that VEGF and its mRNA work together to promote their development and to increase their resistance to chemotherapy drugs. They suggest that combining therapies that prevent the production of vegf mRNA (for example, siRNA-based gene silencing) with therapies that block the function of VEGF might improve survival times for patients whose tumors overexpress VEGF.
###end p 17
###begin title 18
Additional Information.
###end title 18
###begin p 19
Please access these Web sites via the online version of this summary at .
###end p 19
###begin p 20
###xml 37 50 37 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLoS Medicine</italic>
This study is discussed further in a PLoS Medicine
###end p 20
###begin p 21
The US National Cancer Institute provides information about all aspects of , including information on , and on , an anti-VEGF therapeutic (in English and Spanish)
###end p 21
###begin p 22
, from Emory University, provides information on all aspects of cancer, including  (in several languages)
###end p 22
###begin p 23
 also provides basic information about what causes cancers and how they develop, grow, and spread, including information about
###end p 23
###begin p 24
Wikipedia has pages on  and on  (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 24
###begin title 25
Introduction
###end title 25
###begin p 26
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b001">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b004">4</xref>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b005">5</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b010">10</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b011">11</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b012">12</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b013">13</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b014">14</xref>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b015">15</xref>
###xml 1119 1123 1119 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor-A (VEGF) is one of the key regulators in tumor formation and progression [1-4]. The clinical significance of VEGF in tumors has been demonstrated by many studies showing that the VEGF expression level is correlated with tumor grade, depth of invasion, status of nodal and distant metastasis, and clinical stage [5-10]. In addition, high levels of circulating VEGF are associated with resistance to chemotherapy in patients with metastatic solid tumors, including colorectal cancer [11,12]. The stimulatory action of VEGF on tumor angiogenesis is believed to play a central role in promotion of tumor development. At the same time, VEGF is known to act as an autocrine survival and growth factor for tumor cells [13]. Based on the evidence outlined above, a number of strategies to target VEGF or VEGF receptors (VEGFR) have been developed and subjected to clinical evaluation [14]. In contrast to preclinical studies in animal models, clinical trials suggest that anti-VEGF monotherapy was less effective than standard chemotherapy [15], raising the possibility that VEGF or possibly vegf mRNA might possess unrecognized function(s).
###end p 26
###begin p 27
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b016">16</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b017">17</xref>
###xml 394 406 390 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-tropomyosin</italic>
###xml 413 415 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b018">18</xref>
###xml 431 441 427 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">prohibitin</italic>
###xml 448 450 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b019">19</xref>
###xml 466 490 462 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ribonucleotide reductase</italic>
###xml 497 499 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b020">20</xref>
###xml 519 524 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 531 533 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b021">21</xref>
###xml 665 669 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 794 796 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b022">22</xref>
###xml 797 799 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b023">23</xref>
###xml 98 103 <span type="species:ncbi:9606">human</span>
A recent report has shown that VEGF protein functions as an internal autocrine survival factor in human breast cancer cells through internally expressed VEGFR [16]. In addition, non-coding RNAs have now been recognized to play critical roles in tumorigenesis [17]. One class of the tumor-associated non-coding RNAs is the untranslated region (UTR) of certain mRNAs, including the 3'UTR of alpha-tropomyosin mRNA [18], the 3'UTR of prohibitin mRNA [19], the 3'UTR of ribonucleotide reductase mRNA [20], and the 5'UTR of c-myc mRNA [21]. All of these UTR RNAs function as tumor suppressors. From this point of view, we directed our attention to a unique structure of vegf mRNA characterized by its unusually long 5'UTR (1,038 nucleotide [nt]) containing two internal ribosome entry sites (IRES) [22,23].
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
Reagents
###end title 29
###begin p 30
###xml 117 120 109 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 135 138 127 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 12 17 <span type="species:ncbi:9606">human</span>
Recombinant human (rh) interferon alpha (IFNalpha) was purchased from PBL Biomedical Laboratories. rhIFNgamma, rhVEGF165, and anti-VEGF165-neutralizing monoclonal antibody (Ab) were from R&D Systems.
###end p 30
###begin title 31
Cell Culture and Transfection
###end title 31
###begin p 32
###xml 406 409 406 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 271 276 <span type="species:ncbi:9606">human</span>
The human colon carcinoma cell lines (HCT116 and RKO) were maintained in McCoy's 5A medium, supplemented with 10% (v/v) FCS and antibiotics. The human embryonic kidney cell line (HEK293) was maintained in DMEM medium, supplemented with 10% (v/v) FCS and antibiotics. The human gastric carcinoma cell line (AGS) was maintained in F-12 medium, supplemented with 10% (v/v) FCS and antibiotics. Amounts of VEGF165 secreted into the culture medium were measured by ELISA assay (Quantikine, R&D Systems), according to the manufacturer's instructions.
###end p 32
###begin p 33
Transfection of cells was performed using the jetPEI (Polyplus-transfection) or FuGENE HD (Roche Diagnostics) transfection reagent, according to the manufacturer's instructions. We checked the transfection efficiency by monitoring expression of yellow fluorescent protein (YFP)-expressing plasmid and determined the efficiency to be 60%-65% in HCT116 cells, 80%-85% in HEK293 cells, 60%-65% in RKO cells, and 60%-65% in AGS cells.
###end p 33
###begin title 34
Cell Growth
###end title 34
###begin p 35
Cell growth was assessed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega), according to the manufacturer's instructions. Cells were plated in a 96-well flat-bottom plate and cultured in 100 mul of McCoy's 5A medium containing 10% (v/v) FCS and antibiotics, and the MTT reagent (20 mul/well) was added to each well and incubated for 1 h. The levels of blue formazan were measured spectrophotometrically at 490 nm at each time point using a microplate reader (Wallac 1420 ARVO MX; Perkin Elmer).
###end p 35
###begin p 36
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 342 343 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To assess anchorage-independent growth, cells (1 x 105) were plated in 2 ml of McCoy's 5A medium containing 10% (v/v) FCS and 0.33% agar. This suspension was layered over a 3-ml base layer of solidified McCoy's medium containing 10% (v/v) FCS and 0.5% agar in 60-mm diameter culture dishes. Following a 28-d incubation at 37 degreesC in 5% CO2, the number of colonies (approximately >0.1 mm in diameter) with dense centers was scored for each plate.
###end p 36
###begin title 37
Assessment of Apoptosis
###end title 37
###begin p 38
Apoptotic cells were assessed by the TUNEL-staining method using an in situ Cell Death Detection kit (Roche Diagnostics). TUNEL-positive cells were viewed using a microscope, and percentages of the positive cells were calculated. A minimum of 300 cells was counted for each determination. Apoptosis was also detected using the APOPercentage apoptosis assay kit (Biocolor), according to the manufacturer's instructions. The APOPercentage dye stains cells undergoing the membrane "flip-flop" event when phosphatidylserine is translocated to the outer leaflet. This event is specific for apoptosis, but not for necrosis.
###end p 38
###begin p 39
The caspase 3/7 activity was measured using the Caspase-Glo 3/7 assay (Promega), according to the manufacturer's instructions. After cells were treated with 80 muM of 5-fluorouracil (5-FU) for 24 h, the Caspase-Glo 3/7 reagent was added to each well and incubated for 1 h. The luminescence was measured using a microplate-reading luminometer (Wallac 1420 ARVO MX; Perkin Elmer).
###end p 39
###begin title 40
Plasmid Constructions and Establishment of Stable Transfectants
###end title 40
###begin p 41
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 371 375 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 918 926 918 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
The plasmids expressing vegf small-interfering RNAs (siRNAs) were constructed using a BLOCK-iT Pol II miR RNAi expression vector kit (Invitrogen), in accordance with the manufacturer's protocol. A pcDNA6.2-GW/EmGFP-miRNA vector that contains the GFP-coding region within the pre-miRNA expression cassette was inserted with the following pairs of sense and antisense DNA: vegf siRNA number 1, 5'-TGC TGA GCA AGG CAA GGC TCC AAT GCG TTT TGG CCA CTG ACT GAC GCA TTG GAC TTG CCT TGC T-3' (sense) and 5'-AGC AAG GCA AGT CCA ATG CGT CAG TCA GTG GCC AAA ACG CAT TGG AGC CTT GCC TTG CTC AGC A-3' (antisense); vegf siRNA number 2, 5'-TGC TGA GAG CAG CAA GGC AAG GCT CCG TTT TGG CCA CTG ACT GAC GGA GCC TTC TTG CTG CTC T-3' (sense) and 5'-AGA GCA GCA AGA AGG CTC CGT CAG TCA GTG GCC AAA ACG GAG CCT TGC CTT GCT GCT CTC AGC A-3' (antisense). These siRNAs were cloned into pcDNA6.2-GW/EmGFP-miRNA vector (siVEGF#1 and siVEGF#2 in Figure 1). As a control siRNA-expressing plasmid, we used the pcDNA6.2-GW/EmGFP-miR-negative control plasmid expressing mature siRNA that is predicted not to target any known vertebrate genes (Invitrogen).
###end p 41
###begin title 42
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effect of vegf Transcript on Susceptibility to Anti-Cancer Drugs
###end title 42
###begin p 43
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 179 180 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) Knockdown efficiency of vegf mRNA. Expression levels of vegf mRNA were measured using quantitative RT-PCR. Values were normalized for the amount of gapdh mRNA (means +/- SEM, n = 4).
###end p 43
###begin p 44
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 484 485 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(B) Knockdown of vegf mRNA increases 5-FU induced apoptosis. Cells untransfected (-) or transfected with the indicated plasmids for 24 h were treated with 20 muM 5-FU or rhVEGF protein (1, 2, 4, or 6 ng/ml) combined with 5-FU (20 muM) for 48 h. Apoptosis was evaluated by calculating the percentages of TUNEL-positive cells. Values are means +/- SEM from four independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 44
###begin p 45
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 269 272 268 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 578 579 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 259 264 <span type="species:ncbi:9606">human</span>
(C) Overexpression of vegf transcript induces resistance to 5-FU. Cells were transfected with a plasmid encoding full-length vegf mRNA or an empty vector (mock) for 24 h. The cells were treated without or with 80 muM 5-FU in the presence of a monoclonal anti-human VEGF165-neutralizing Ab at the indicated concentrations for 48 h, and then apoptotic cells were identified and quantitated by the TUNEL-staining method. Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 45
###begin p 46
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b024">24</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b027">27</xref>
###xml 137 145 137 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 394 397 394 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdgf-b</italic>
###xml 539 546 539 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 667 670 667 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 409 414 <span type="species:ncbi:9606">human</span>
###xml 432 437 <span type="species:ncbi:9606">human</span>
###xml 459 464 <span type="species:ncbi:9606">human</span>
###xml 661 666 <span type="species:ncbi:9606">human</span>
###xml 679 684 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
The following plasmid constructs were kindly provided by Drs. Herve Prats and Anne-Catherine Prats [24-27]: pAUG165mSPHA (construct I in Figure 2A), p165mSPHA 3' (construct II), pVC (construct V), pSCT-chloramphenicol acetyltransferase (CAT) (construct IX), pVCTTT (construct XI), the plasmids expressing a chimeric mRNA fused to CAT coding sequence comprising one of the constructs (the human bip 5'UTR, the human c-myc 5'UTR, the human fgf-2 5'UTR, and the human pdgf-b 5'UTR), and the bicistronic plasmid contains two luciferase genes, Renilla luciferase (LucR) and firefly luciferase (LucF), which are separated by a hairpin (hairpin control) or an IRES of human bip (pRBL), human c-myc (pRMyP2L), and human fgf-2 (pRFL).
###end p 46
###begin title 47
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effects of vegf 5'UTR RNA on Resistance to 5-FU
###end title 47
###begin p 48
(A) Schematic of the constructs transfected into HCT116 cells. mSP, mutated signal peptide; HA, hemagglutinin.
###end p 48
###begin p 49
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 408 409 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(B) The vegf 5'UTR induces 5-FU resistance. Cells untransfected (-) or transfected with the indicated construct for 24 h were treated with 80 muM 5-FU for 48 h, and then apoptotic cells were identified and quantitated by the TUNEL-staining method. Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 49
###begin p 50
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 419 420 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C) Determination of functional element in the vegf 5'UTR. Cells untransfected (-) or transfected with the indicated construct for 24 h were treated with 80 muM 5-FU for 48 h. Apoptotic cells was then measured by the TUNEL-staining method as described above. Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 50
###begin p 51
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 450 451 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(D) The vegf 5'UTR-mediated resistance to 5-FU is independent of de novo protein synthesis. Cells transfected with the indicated plasmids for 24 h were treated with 80 muM 5-FU in the absence or presence of CHX (1 or 10 mug/ml) for 40 h. Apoptosis was assessed by the TUNEL-staining method. Values are means +/- SEM from four independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 51
###begin p 52
###xml 115 118 115 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 269 277 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 726 730 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 888 889 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</italic>
###xml 961 965 961 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1076 1080 1076 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1609 1617 1609 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1737 1741 1737 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1817 1819 1817 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b028">28</xref>
p165mSPHA 3' and p165AUGmSPHA have H9D and L14E mutations in the signal sequence that prevent secretion of the VEGF165 protein. p165mSPHA 3' was digested with ClaI and ApaI, blunted by Klenow treatment, and religated. The resulting plasmid (p165mSPHA, construct III in Figure 2A) did not contain the 3'UTR sequence. p165mSPHA 3' was digested with XbaI and NgoMIV, blunted by Klenow treatment, and religated. The resulting plasmid (pAUG165mSPHA 3', construct IV) did not encode the 5'UTR sequence. Several deletion constructs of the vegf 5'UTR were also made from the pVC plasmid by digestion with NgOMIV (construct VI), XbaI and NheI (construct VII), or BamHI (construct VIII). We also prepared a plasmid encoding full-length vegf mRNA with an intact signal peptide sequence. The construct pVC, which has an intact signal sequence, was digested with NarI and BsaBI, and the resultant NarI-BsaBI fragment was ligated into p165mSPHA 3' to reconstruct full-length vegf mRNA with an intact signal peptide sequence (p165HA 3'). A construct mutated between nt 591 and nt 746 of the vegf 5'UTR was synthesized using two serial double-stranded DNA fragments (mutations are indicated by lower case letters): nt 576 -GCG AGC CGC GGG CAa GGa CCa GAa CCa GCa CCa GGg GGa GGa GTa GAa GGa GTa GGG GCT C- nt 636 and nt 637- GGGCT CGa GGa GTa GCa tta AAg CTa TTt GTa CAg tta tta GGa TGc TCa CGa TTt GGg GGg GCa GTa GTa aga GCa GGa GAg GCa GAa CCa AGt GGg GCa GCa AGg AGT GCT AGC- nt 752. The two synthesized fragments were ligated and inserted into pVC digested with SacII and NheI to generate plasmid pVCmut (construct X in Figure 2A). All the constructs were confirmed to have the expected sequences using a DNA sequencer. The secondary structures of vegf 5'UTR and its mutant were analyzed using the mfold 3.2 algorithm of Zuker [28].
###end p 52
###begin p 53
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
We also constructed a plasmid expressing a chimeric mRNA comprising the vegf 5'UTR fused to YFP. The constructs pVC and pVCmut were digested with EcoRI and NcoI, and the resulting EcoRI-NcoI fragments were ligated into pd2EYFP-N1 (Clontech) to generate pVY and pVYmut, respectively.
###end p 53
###begin p 54
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 501 505 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 517 521 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Stable transfectants were constructed using early passages of HCT116 cells that had been plated at approximately 1 x 105 in a 60-mm diameter culture dish and cultured overnight. The cells were transfected with 5 mug of pYFP, pVY, pVYmut, siVEGF#1, or pcDNA6.2-GW/EmGFP-miRNA-neg control plasmids. Clones were selected and maintained in McCoy's 5A medium supplemented with 450 mug/ml G418 (Invitrogen), or with 5 mug/ml Blasticidin (Invitrogen). Three stably transfected cell lines (HCT116/YFP, HCT116/vegf 5', HCT116/vegf 5'mut, HCT116/siVEGF, or HCT116/siControl) were isolated after 28 d of selection.
###end p 54
###begin title 55
Western and Northern Blot Analyses
###end title 55
###begin p 56
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b029">29</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b026">26</xref>
###xml 719 729 716 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg010">Figure S10</xref>
###xml 201 207 <span type="species:ncbi:9986">rabbit</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 320 325 <span type="species:ncbi:10090">mouse</span>
###xml 348 353 <span type="species:ncbi:9606">human</span>
###xml 457 463 <span type="species:ncbi:9986">rabbit</span>
###xml 547 552 <span type="species:ncbi:10090">mouse</span>
###xml 761 766 <span type="species:ncbi:9606">human</span>
Cell lysates were prepared using a lysis buffer containing 100 mM Tris-HCl (pH 6.8), 300 mM NaCl, 2 mM EDTA, and 4% (v/v) SDS. Western immunoblotting was performed as described previously [29] using a rabbit polyclonal anti-human influenza virus hemagglutinin (HA) Ab (Santa Cruz Biotechnology) at a 1/1,000 dilution, a mouse monoclonal Ab against human signal transducers and activators of transcription 1 (STAT1) (Cell Signaling) at a 1/1,000 dilution, a rabbit polyclonal anti-L-VEGF Ab at a 1/500 dilution (a gift from Herve Prats) [26], or a mouse anti-beta-actin monoclonal Ab (Sigma). The specificity of individual antibody reactivity was confirmed by the absorption test with the corresponding antigen peptide (Figure S10). Blocking antigen peptide for human STAT1 and HA were obtained from Cell Signaling and Santa Cruz Biotechnology, respectively. Antigen peptides for L-VEGF were synthesized using an Applied Biosystems 432A peptide synthesizer.
###end p 56
###begin p 57
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b029">29</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 465 467 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Total RNA was prepared by the guanidinium thiocyanate method. Northern hybridization was performed as described previously [29] using following cDNA probes. cDNA probes for vegf 5'UTR RNA and vegf ORF RNA were prepared by digestion of the plasmid p165mSPHA 3' with NgoMIV and ClaI, and SacII and NheI, respectively. A cDNA probe for CAT mRNA was prepared as a digestion fragment of the plasmid pVC using EcoRI and BglII sites. These probes were labeled with [alpha-32P]dCTP using Klenow enzyme (New England BioLabs), according to the manufacturer's instructions.
###end p 57
###begin title 58
Animal Studies and Immunohistochemistry
###end title 58
###begin p 59
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 552 553 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 737 738 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 149 158 <span type="species:ncbi:10090">nude mice</span>
###xml 385 394 <span type="species:ncbi:10090">nude mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 681 690 <span type="species:ncbi:10090">nude mice</span>
The use of animals in the experiments described here was approved by the Animal Care Committee of University of Tokushima. Seven-wk-old male athymic nude mice (Nippon SLC) were caged in groups of five and acclimated for 1 wk. A cell suspension (5 x 106 cells) in serum-free McCoy's 5A medium, prepared from each stably transfected clone, was injected subcutaneously into the flanks of nude mice. The sizes of tumors that developed in the injected mice were measured in two dimensions with a caliper and their volumes calculated using the formula (L x W2) x 0.5, where L is length and W is width. We confirmed that parental HCT116 cells (5 x 106 cells) injected subcutaneously into nude mice formed tumors whose volumes were around 500 mm3 day 28 after transplantation. Therefore, HCT116/YFP clones appeared to form xenograft tumors less efficiently than parental HCT116 cells, probably because expression of YFP and/or procedures during the establishment of permanent cell cloning was likely to nonspecifically reduce the tumor-forming capability.
###end p 59
###begin p 60
###xml 5 9 <span type="species:ncbi:10090">mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 352 357 <span type="species:ncbi:10090">mouse</span>
###xml 484 487 <span type="species:ncbi:10116">rat</span>
###xml 493 498 <span type="species:ncbi:10090">mouse</span>
Some mice were injected intraperitoneally with BrdU (1.5 g/kg body weight, Sigma-Aldrich) 2 h before they were humanely killed. The mice were killed on the indicated days, and growing tumors were removed and fixed with formalin in PBS. The fixed xenografts were sectioned and stained with hematoxylin and eosin (HE), or by immunohistochemistry using a mouse monoclonal anti-BrdU Ab (Sigma-Aldrich), or by a DeadEnd colorimetric TUNEL System (Promega). Vasculature was stained using a rat anti-mouse CD31 Ab (BD Pharmingen).
###end p 60
###begin p 61
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 176 185 <span type="species:ncbi:10090">nude mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 556 561 <span type="species:ncbi:10090">mouse</span>
We also examined the effects of 5-FU on implanted tumors. In this experiment, HCT116/vegf 5' transfectants (5 x 106 cells) were injected subcutaneously into the left flanks of nude mice, and HCT116/YFP (1 x 107 cells) or HCT116/vegf 5'mut transfectants (1 x 107 cells) were injected into the right flanks of the same mice. When the tumors reached a size of approximately 40 mm3, usually by day 7, the mice were treated daily with an intraperitoneal injection of 5-FU (30 mg/kg weight, Sigma-Aldrich), or with 5-FU (30 mg/kg weight) plus IFNalpha (50,000 U/mouse; PBL Biomedical Laboratories). The tumor sizes were measured daily using a caliper, and their volumes were calculated as described above.
###end p 61
###begin title 62
Microarray Analysis
###end title 62
###begin p 63
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 468 472 468 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 665 669 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 731 735 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1381 1385 1380 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 16 21 <span type="species:ncbi:9606">Human</span>
###xml 796 801 <span type="species:ncbi:9606">Human</span>
We used Agilent Human 1A oligomicroarrays (Agilent Technologies) containing 60-mer DNA probes synthesized in situ in a 22-k format. Total RNA was prepared from three independent vegf 5'-G5 tumors on day 14, and an equal amount of RNA from each tumor was mixed. After contaminating DNA had been removed using a DNase kit (Qiagen), the resultant RNA quality was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA was also prepared from three vegf 5'mut-D5 tumors on day 14 in the same manner. Synthesis, amplification, and labeling of cRNA were carried out in accordance with the manufacturer's protocol. Cy5-cRNA (0.75 mug) prepared from vegf 5'-G5 tumors was mixed with the same amount of Cy3-cRNA from vegf 5'mut-D5 tumors. Hybridization was performed on the Agilent Human 1A oligomicroarray (Agilent Technologies), according to the manufacturer's protocol. Fluorescence images of the hybridized microarrays were obtained using an Agilent microarray scanner (G2565BA). Signal intensities of Cy5 and Cy3 were quantified and analyzed by subtracting the backgrounds using feature extraction software (Agilent, version 9.5). The Cy5/Cy3 ratios of 12,178 genes that had a higher fluorescence value than 100 for both Cy5 and Cy3 signals were transformed to logarithms for global normalization. We selected genes whose mRNA levels differed by >2-fold between vegf 5'-G5 and mut-D5 tumors.
###end p 63
###begin title 64
Dual-Luciferase Assay
###end title 64
###begin p 65
To measure IRES activity, we used the bicistronic plasmid. The bicistronic cassette expresses the LucR in a cap-dependent manner and LucF in an IRES-dependent manner. Each IRES or hairpin control is located between the two cistrons.
###end p 65
###begin p 66
To measure IFN-dependent transcriptional activity, we used plasmids containing the motifs IFN-stimulated regulatory element (ISRE) and IFN-gamma-activated sequence (GAS) upstream of the LucF reporter gene (Pathway Profiling Luciferase System).
###end p 66
###begin p 67
LucF and LucR activities were measured using the Dual-Luciferase reporter assay system (Promega), according to the manufacturer's instructions. Transfected cells were rinsed twice with PBS, scraped, and homogenized in 50 mul of lysis reagent provided with the kit. The lysate was cleared by a 2-min centrifugation at 4 degreesC. Chemiluminescent signals were measured in a luminometer (Wallac 1420 ARVO MX; Perkin Elmer) equipped with automatic injectors.
###end p 67
###begin title 68
Quantitative Real-Time PCR
###end title 68
###begin p 69
###xml 281 284 280 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mia</italic>
###xml 302 306 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl6</italic>
###xml 324 328 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">egfr</italic>
###xml 346 350 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrg1</italic>
###xml 368 373 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pcdc1</italic>
###xml 391 394 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fas</italic>
###xml 412 415 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bax</italic>
###xml 433 437 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xaf1</italic>
###xml 455 465 454 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trail/apo2</italic>
###xml 483 486 482 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nmi</italic>
###xml 504 509 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">isg20</italic>
###xml 527 531 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1</italic>
###xml 549 553 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas2</italic>
###xml 571 575 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">irf1</italic>
###xml 593 596 592 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pml</italic>
###xml 618 623 617 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 686 692 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar1</italic>
###xml 694 700 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar2</italic>
###xml 702 708 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr1</italic>
###xml 714 720 713 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr2</italic>
###xml 739 745 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr1</italic>
###xml 747 753 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr2</italic>
###xml 755 759 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp1</italic>
###xml 764 768 763 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp2</italic>
###xml 771 776 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 778 782 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 877 883 873 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar1</italic>
###xml 981 987 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar2</italic>
###xml 1100 1106 1096 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr1</italic>
###xml 1203 1209 1199 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr2</italic>
###xml 1306 1312 1302 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr1</italic>
###xml 1408 1414 1404 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr2</italic>
###xml 1514 1518 1510 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp1</italic>
###xml 1607 1611 1603 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp2</italic>
###xml 1701 1706 1697 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 1802 1806 1798 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 2302 2307 2295 2300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
SuperScript II RNase H-reverse transcriptase (Invitrogen) was used to synthesize cDNAs from 1 mug aliquots of total RNA prepared from three independent tumor tissues. Taqman Gene Expression assays (Applied Biosystems) were used with the following cDNA-specific primers and probes: mia (Hs00197954_m1); bcl6 (Hs00153368_m1); egfr (Hs00193306_m1); nrg1 (Hs00247624_m1); pcdc1 (Hs00169472_m1); fas (Hs00531110_m1); bax (Hs00180269_m1); xaf1 (Hs00213882_m1); trail/apo2 (Hs00234356_m1); nmi (Hs00190768_m1); isg20 (Hs00158122_m1); oas1 (Hs00242943_m1); oas2 (Hs00213443_m1); irf1 (Hs00233698_m1); pml (Hs00231241_m1); and gapdh (Hs99999905_m1). The levels of transcripts for IFN receptors (ifnar1, ifnar2, ifngr1, and ifngr2), VEGF receptors (vegfr1, vegfr2, nrp1 and nrp2), stat1, vegf, and beta-actin were measured by real time (RT)-PCR using the following specific primer sets: ifnar1, 5'-CCC AGT GTG TCT TTC CTC AAA-3' (forward) and 5'-AAG ACT GGA GGA AGT AGG AAA GC-3' (reverse); ifnar2, 5'-AGT CAG AGG GAA TTG TTA AGA AGC A-3' (forward) and 5'-TTT GGA ATT AAC TTG TCA ATG ATA TAG GTG-3' (reverse); ifngr1, 5'-GGT GTG AGC AGG GCT GAG-3' (forward) and 5'-GTA ACA TTA GTT GGT GTA GGC ACT G-3' (reverse); ifngr2, 5'-GGC CTG ATT AAA TAC TGG TTT CA-3' (forward) and 5'-GGG CTG AGT TGG GTC TTT TA-3' (reverse); vegfr1, 5'-AGA ACC CCG ATT ATG TGA GAA A-3' (forward) and 5'-GAT AGA TTC GGG AGC CAT CC-3' (reverse); vegfr2, 5'-GAA CAT TTG GGA AAT CTC TTG C-3' (forward) and 5'-CGG AAG AAC AAT GTA GTC TTT GC-3' (reverse); nrp1, 5'-CCC TGA GAA TGG GTG GAC T-3' (forward) and 5'-CGT GAC AAA GCG CAG AAG-3' (reverse); nrp2, 5'-GGA CCC CCA ACT TGG ATT-3' (forward) and 5'-ATG GTT AAA AAG CGC AGG TC-3' (reverse); stat1, 5'-CTG CTC CTT TGG TTG AAT CC-3' (forward) and 5'-GCT GAA GTT CGT ACC ACT GAG A-3' (reverse); vegf, 5'-GAG CCT TGC CTT GCT GCT CTA C-3' (forward) and 5'-CAC CAG GGT CTC GAT TGG ATG-3' (reverse); beta-actin, 5'-CCA ACC GCG AGA AGA TGA-3' (forward) and 5'-CCA GAG GCG TAC AGG GAT AG-3' (reverse). Amplification and quantification of the PCR products were performed using the Applied Biosystems 7500 System (Applied Biosystems). Standards were run in the same plate and the relative standard curve method was used to calculate the relative mRNA expression. RNA amounts were normalized against the gapdh mRNA level.
###end p 69
###begin title 70
Statistical Analysis
###end title 70
###begin p 71
###xml 54 55 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The data were analyzed using the two-tailed Student's t-test or ANOVA and the Scheffe's test. A p-value of less than 0.05 was considered significant.
###end p 71
###begin title 72
Results
###end title 72
###begin title 73
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effect of vegf mRNA on Apoptosis Caused with Anti-Cancer Drugs
###end title 73
###begin p 74
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 139 148 139 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg006">Figure S6</xref>
###xml 181 184 181 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 219 220 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 241 245 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 300 304 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 327 335 323 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
###xml 500 503 495 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 555 558 550 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 586 587 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 722 725 714 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 772 776 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 802 810 794 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
###xml 835 838 827 830 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
First, we investigated whether vegf mRNA possessed a tumor-promoting activity in HCT116 cells that expressed VEGFR-2 and Neuropilin-1, -2 (Figure S6) and secreted spontaneously VEGF165 at 759 +/- 32 pg/ml (mean +/- SD, n = 4). Two different vegf-targeting siRNAs successfully knocked down endogenous vegf mRNA in HCT116 cells (Figure 1A). This silencing made the cells susceptible to apoptosis caused with a low concentration of 5-FU (20 muM). We then examined the effect of supplementation of rhVEGF165 in the knockdown cells. The amount of secreted VEGF165 increased to 1,018 +/- 48 (n = 4) from the cells that were untransfected and treated with 5-FU (20 muM) for 48 h. An external supplementation of 1,000 pg/ml rhVEGF165 failed to block the 5-FU-induced apoptosis in vegf siRNA-transfected cells (Figure 1B). Treatment with rhVEGF165 at 2,000 pg/ml or higher significantly, but not completely, prevented the apoptosis.
###end p 74
###begin p 75
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 90 93 90 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 180 183 179 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 205 206 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 295 303 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
###xml 340 343 337 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 515 518 511 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 521 529 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
###xml 614 618 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 788 797 784 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg001">Figure S1</xref>
###xml 803 805 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg001">S1</xref>
In contrast, cells were transiently transfected with a plasmid expressing full-length vegf165 mRNA and exposed to a higher concentration of 5-FU (80 muM). These cells secreted VEGF165 (7,092 +/- 23 pg/ml, n = 4) during the experimental period and exhibited resistance to 5-FU-induced apoptosis (Figure 1C). It should be noted that anti-VEGF165-neutralizing monoclonal Ab could not completely cancel the anti-apoptotic activity even at concentrations of up to 5 mug/ml (about 250 molar excess amount of secreted VEGF165) (Figure 1C). Both knockdown and overexpression experiments suggest that both VEGF protein and vegf mRNA may possess an anti-apoptotic function. Similar or even clearer results were observed in the cells treated with other anti-cancer drugs, etoposide and doxorubicin (Figure S1A and S1B).
###end p 75
###begin title 76
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effect of vegf mRNA 5'UTR on Apoptosis Caused by 5-FU
###end title 76
###begin p 77
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 42 45 42 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 175 183 175 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 250 253 250 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b026">26</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 364 367 364 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 377 386 377 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg002">Figure S2</xref>
###xml 456 459 456 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 548 551 548 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 616 624 615 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g001">Figure 1</xref>
###xml 748 756 747 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 762 771 761 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">Figure S3</xref>
###xml 856 859 855 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1068 1076 1067 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1188 1197 1187 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg001">Figure S1</xref>
###xml 1203 1205 1202 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg001">S1</xref>
Next, we used the mutated full-length vegf165 mRNA-expressing plasmid that has mutations of two amino acid residues within the signal peptide, shown as "mSP" in construct II (Figure 2A). This plasmid-derived mRNA is translated into a nonsecreted VEGF165 protein [26]. We confirmed that cells transfected with this construct expressed full-length vegf mRNA and VEGF165 protein (Figure S2A), but did not secrete detectable amounts of the plasmid-derived VEGF165 (unpublished data). As was described above, HCT116 cells overexpressing full-length vegf165 mRNA without mutation were completely resistant to 80 muM 5-FU (Figure 1C). In contrast, cells transfected with construct II significantly, but not completely, blocked the 5-FU-induced apoptosis (Figure 2B and Figure S3A). This partial loss of anti-apoptotic activity was probably due to the lack of VEGF165-secreting activity. Next, we prepared the constructs lacking the 3'UTR (construct III), 5'UTR (construct IV), or both (construct I), and found that the 5'UTR was associated with the chemoresistant phenotype (Figure 2B). Similar results were observed in the cells treated with other anti-cancer drugs, etoposide and doxorubicin (Figure S1C and S1D).
###end p 77
###begin p 78
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 115 123 115 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 229 237 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 330 338 330 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 491 499 491 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b022">22</xref>
To confirm the functional role of the 5'UTR, we used a plasmid expressing the vegf 5'UTR fused to CAT coding gene (Figure 2A, construct V), which does not express VEGF protein. This chimeric mRNA retained the resistance to 5-FU (Figure 2C). We then designed several deletion constructs of the chimeric mRNA (constructs VI-VIII in Figure 2A), and found that the 270-nt-long element delimited by positions nt 475 and nt 745 in the 5'UTR sequence was crucial for the drug-resistance phenotype (Figure 2C). This sequence is just upstream of IRES-A, but does not require the IRES activity [22].
###end p 78
###begin p 79
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b024">24</xref>
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 579 588 579 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg005">Figure S5</xref>
###xml 735 739 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 834 843 834 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg002">Figure S2</xref>
###xml 890 898 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1032 1040 1032 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b024">24</xref>
###xml 1093 1102 1093 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg002">Figure S2</xref>
###xml 1187 1195 1187 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1521 1522 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1556 1557 1548 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1615 1623 1606 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 1643 1647 1634 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1672 1676 1663 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
It is known that the 5'UTR of human vegf mRNA encodes long N-terminal VEGF proteins (termed L-VEGF) that are translated from CUG codons upstream of and in-frame with the classical AUG start codon [24]. To eliminate the possibility that the L-VEGF proteins might induce the chemoresistance, we designed a mutated 5'UTR construct that produced L-VEGF protein, but modified the RNA structure by substituting the nucleic acid sequence between nt 591 and nt 746 (construct X in Figure 2A). Secondary structures of the vegf 5'UTR and its mutated 5'UTR were predicted by mFold program (Figure S5). The mutation changed the secondary structure of several parts and ablated a stem-loop structure that is located in the functional region of the vegf 5'UTR (nt 699 to nt 738) as described above. The mutated construct X produced L-VEGF protein (Figure S2B), but did not induce the resistance to 5-FU (Figure 2C). We also used a simply mutated 5'UTR, in which the first CUG codon was substituted into a noninitiating UUU codon (construct XI in Figure 2A) [24]. This mutant did not produce L-VEGF protein (Figure S2B), but was able to induce the resistance as efficiently as did the wild-type 5'UTR (Figure 2C). We further examined the effect of a protein synthesis inhibitor, cycloheximide (CHX). To determine the inhibitory effect of CHX, HCT116 cells were transfected with plasmid encoding luciferase in the absence or presence of CHX, and luciferase activity was measured. Protein synthesis was blocked by 86 +/- 5% (mean +/- SD, n = 3) and 94 +/- 3% (mean +/- SD, n = 3) with 1 and 10 mug/ml CHX, respectively. As shown in Figure 2D, both full-length vegf mRNA (construct II) and vegf 5'UTR-CAT mRNA (construct V) efficiently inhibited 5-FU-induced apoptosis even in the presence with 10 mug/ml CHX. These results suggest that the 5'UTR-mediated chemoresistance may not require de novo protein synthesis.
###end p 79
###begin p 80
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 139 148 139 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">Figure S3</xref>
###xml 207 216 207 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">Figure S3</xref>
###xml 416 425 416 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">Figure S3</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">S3</xref>
###xml 558 567 558 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg003">Figure S3</xref>
In addition to the TUNEL-staining method, we evaluated the vegf 5'UTR-mediated anti-apoptotic effect by the Apopercentage-staining method (Figure S3C) and by measuring activities of caspase 3 and caspase 7 (Figure S3D), which are crucial effector enzymes for apoptosis induced by genotoxic agents. We confirmed that the results obtained by the Apopercentage-staining method were similar to those by the TUNEL assay (Figure S3B and S3C). Cells transfected with construct II, V, and XI significantly, but not completely, blocked the activation of caspase 3/7 (Figure S3D).
###end p 80
###begin p 81
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b030">30</xref>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdgf-b</italic>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b031">31</xref>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 455 464 455 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg004">Figure S4</xref>
To examine whether this anti-apoptotic function is peculiar to vegf mRNA 5'UTR, we used three 5'UTRs containing IRES (c-myc, bip, and fgf-2 mRNA 5'UTRs) [30] and the pdgf-b mRNA 5'UTR that is unusually long, but does not contain IRES activity [31]. After transfection with plasmid expressing one of the indicated 5'UTR-CAT mRNAs, apoptosis was assessed by the TUNEL-staining method. Only the vegf 5'UTR induced the resistance to 5-FU among 5'UTRs tested (Figure S4).
###end p 81
###begin p 82
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 246 255 246 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg006">Figure S6</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg006">S6</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 86 91 <span type="species:ncbi:9606">human</span>
We also examined whether the vegf 5'UTR similarly induce the chemoresistance in other human cancer cell lines (RKO, HEK293, and AGS cells), and confirmed that both full-length vegf mRNA and vegf 5'UTR RNA induced 5-FU resistance in these cells. (Figure S6B-S6D). These observations suggest that the vegf 5'UTR function is not peculiar to HCT116 cells.
###end p 82
###begin p 83
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b022">22</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b023">23</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b030">30</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b032">32</xref>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 550 559 550 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg007">Figure S7</xref>
###xml 620 624 620 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 679 687 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g002">Figure 2</xref>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 853 856 853 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 858 863 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 868 873 868 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 881 890 881 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg007">Figure S7</xref>
The vegf 5'UTR contains IRES sequences that interact with IRES-binding factors and regulate translation initiation in a cap-independent manner [22,23]. Many IRES-containing mRNAs encode proteins that regulate cell growth, differentiation, and apoptosis [30,32]. Thus, overexpression of the vegf 5'UTR raises the possibility that increased amounts of the vegf 5'UTR may trap IRES-binding factors, thereby nonspecifically modifying IRES-dependent expression of genes. To address this issue, we tested the effect of vegf 5'UTR on other IRES activities (Figure S7B). HCT116 cells were cotransfected with plasmids expressing vegf 5'UTR-CAT mRNA (construct V or mutated construct X in Figure 2A) and the bicistronic construct containing 5'UTR of the indicated genes. We confirmed that overexpression of the vegf 5'UTR RNA did not repress the IRES activity of bip, c-myc, or fgf-2 5'UTR (Figure S7B).
###end p 83
###begin title 84
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Characterization of HCT116 Cells Stably Expressing vegf 5'UTR
###end title 84
###begin p 85
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 654 658 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 691 700 691 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg008">Figure S8</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg008">S8</xref>
To investigate chronic effects of the vegf mRNA 5'UTR on malignant transformation of HCT116 cells both in vitro and in vivo, we established stable transfectants that expressed chimeric mRNAs of either the vegf 5'UTR or the mutant one (as described above) fused to the YFP coding gene. Use of these chimeric mRNAs had the following advantages: (i) they did not produce VEGF protein, (ii) expression of these elements could be monitored by YFP fluorescence, and (iii) the chimeric mRNAs were translated similarly as vegf mRNA in our cell system. Ectopic mRNAs were equally expressed in corresponding cell lines and did not modify the amounts of endogenous vegf mRNA and VEGF among the clones (Figure S8A and S8B).
###end p 85
###begin p 86
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 115 123 115 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g003">Figure 3</xref>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 304 312 304 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g003">Figure 3</xref>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 485 489 485 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 524 532 524 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g003">Figure 3</xref>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 679 687 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g003">Figure 3</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g003">3</xref>
The vegf 5'UTR-expressing cells (HCT116/vegf 5', clones G3 and G5) were again resistant to 5-FU-induced apoptosis (Figure 3A). In contrast, the mutant vegf 5'UTR-expressing cells (HCT116/vegf 5'mut, clones D5 and E4) or the transfection control cells (HCT116/YFP, clone G11) underwent apoptosis by 5-FU (Figure 3A). We also examined the growth rate of each clone and observed that the HCT116/vegf 5' exhibited a small, albeit significant increase in growth rate compared to the HCT116/vegf 5'mut and the control HCT116/YFP (Figure 3B). Furthermore, HCT116/vegf 5' displayed a distinctive, anchorage-independent growth, while HCT116/vegf 5'mut and the control HCT116/YFP did not (Figure 3C and 3D).
###end p 86
###begin title 87
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Characterization of HCT116 Cells Stably Expressing the vegf 5'UTR RNA
###end title 87
###begin p 88
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
(A) 5-FU resistance in stable transfectant expressing the vegf 5'UTR RNA. Stably transfected HCT116 clones (HCT116/YFP-G11, HCT116/vegf 5'-G3, HCT116/vegf 5'-G5, HCT116/vegf 5'mut-D5, and HCT116/vegf 5'mut-E4) were treated with 80 muM 5-FU for the indicated time, and then apoptotic cells were identified and quantitated by the TUNEL-staining method. Values are means +/- SEM from three independent experiments.
###end p 88
###begin p 89
###xml 232 233 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(B) Growth rate of the stable transfectants. Cell growth was assessed by MTT assay at the indicated time points. Results are expressed as relative increases in the absorbance, compared with that at time 0. Values are means +/- SEM, n = 4.
###end p 89
###begin p 90
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 461 462 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C and D) Increase in anchorage-independent growth ability in the vegf 5'UTR-expressing clones. The stably transfected clones were cultured in semi-solid medium for 28 d as described in the Methods. Pictures of growing colonies on day 28 are shown in (C), and the number of colonies were counted (D). Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 90
###begin title 91
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Tumor-Forming Activity of the HCT116/vegf 5' Clones
###end title 91
###begin p 92
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 625 629 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 65 74 <span type="species:ncbi:10090">nude mice</span>
To demonstrate the malignancy of HCT116/vegf 5' in vivo, athymic nude mice were injected subcutaneously with each clone, and growing tumor masses were measured. Both HCT116/vegf 5'mut and control HCT116/YFP formed small tumor masses that did not expand further (vegf 5'mut-tumor and YFP-tumor, respectively). In contrast, HCT116/vegf 5' rapidly and progressively formed tumors (vegf 5'-tumor). The average volumes of the vegf 5'-tumors were 4-fold and 41-fold larger than those of the control YFP-tumors on days 5 and 28, respectively (Figure 4B). There was no significant difference between the sizes of tumors derived from vegf 5'-G3 clone and -G5 clone at either time point.
###end p 92
###begin title 93
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Tumor Formation of HCT116 Cells Stably Expressing the vegf 5'UTR RNA In Vivo
###end title 93
###begin p 94
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 421 425 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 458 462 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 477 481 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 547 551 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 566 570 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 607 608 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A and B) In vivo tumorigenesis in xenografts of stable transfectants. Typical examples of growing tumors on day 28 are shown in (A). Tumor growth was assessed up to 28 d after inoculation, and tumor volume (mm3) was calculated by the formula (L x W2 x 0.5). Time-dependent changes in tumor masses are shown in (B). Values are means +/- SEM from six independent experiments. There were no significant differences between vegf 5'-G3 and -G5 or among YFP-G11, vegf 5'mut-D5, and vegf 5'mut-E4 tumors. #, significantly different compared to YFP-G11, vegf 5'mut-D5, and vegf 5'mut-E4 tumors at each time point (p < 0.05 by ANOVA and Scheffe's test).
###end p 94
###begin p 95
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
(C) Immunohistochemistry of the xenografts. On day 28 after inoculation, the growing tumors of vegf 5'-G3 and vegf 5'mut-D5 were subjected to hematoxylin and eosin (HE) staining, immunohistochemistry using a mouse monoclonal Ab against BrdU or CD31, or TUNEL staining. Bars indicate 100 mum in the left photograph in each panel, and 50 mum in the right photograph in each panel.
###end p 95
###begin p 96
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 382 386 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 404 405 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 437 438 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(D) Enhanced proliferation and suppressed apoptosis in the vegf 5'UTR-expressing tumors. Proliferation was assessed by calculating the percentages of BrdU-incorporating cells (left panel). Apoptosis was evaluated by calculating the percentages of TUNEL-positive cells (right panel). Values are means +/- SEM from five independent experiments. #, Significantly different compared to vegf 5'mut-D5 tumors (p < 0.05 by two-tailed Student's t-test).
###end p 96
###begin p 97
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 191 199 191 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 462 470 462 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 573 581 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 602 606 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 658 662 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 726 734 726 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 769 773 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 988 992 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1055 1063 1055 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 1131 1135 1131 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Histological examination showed that the growing vegf 5'-tumors contained central necrotic areas, while the vegf 5'mut-tumors formed a small nest of tumors encapsulated by connective tissue (Figure 4C). We next tested whether the accelerated growth of the vegf 5'-tumors was a consequence of enhanced proliferation, decreased apoptosis, or both. Apoptosis and proliferation were assessed by quantifying TUNEL-positive and BrdU-incorporating cells, respectively (Figure 4C). The vegf 5'-tumors showed a small, but significant increase in the numbers of BrdU-positive cells (Figure 4D) compared with the vegf 5'mut-tumors. The number of apoptotic cells in the vegf 5'-tumor was significantly lower than in the vegf 5'mut-tumor (Figure 4D). These results suggest that the vegf 5'UTR RNA may accelerate tumor growth by suppression of apoptosis and promotion of cell growth. We also examined the development of tumor vessels by staining with an Ab against an endothelial cell marker CD31. The vegf 5'-tumors significantly increased CD31-positive microvessels (Figure 4C) in association with enlargement of the tumors, compared with the vegf 5'mut-tumors.
###end p 97
###begin title 98
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
 Changes in Gene Expression in the vegf 5'-Tumors
###end title 98
###begin p 99
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 463 472 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-st001">Tables S1</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-st002">S2</xref>
###xml 559 563 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 774 777 774 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mia</italic>
###xml 823 826 823 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fas</italic>
###xml 828 833 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pcdc1</italic>
###xml 835 839 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrg1</italic>
###xml 845 848 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bax</italic>
###xml 851 858 851 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050094-t001">Table 1</xref>
Total RNA was prepared on day 14 from three different vegf 5'-tumors, and an equal amount of RNA from each tumor was mixed. Total RNA was also prepared from three different vegf 5'mut-tumors in the same manner. Using a microarray technique, gene expression profiles were compared between the two RNA samples. The vegf 5'-tumors up-regulated mRNA expression of 377 genes and down-regulated 295 genes >2-fold, compared with the vegf 5'mut-tumors (see gene lists in Tables S1 and S2). One of the distinctive identifying features of the listed genes was that the vegf 5'-tumors selectively down-regulated pro-apoptotic genes (eight genes) and up-regulated anti-apoptotic genes (five genes). Quantitative RT-PCR validated the significant up-regulation of an anti-apoptotic gene (mia) and down-regulation of pro-apoptotic genes (fas, pcdc1, nrg1, and bax) (Table 1).
###end p 99
###begin p 100
Validation of Microarray Data on Selected Genes by Quantitative RT-PCR
###end p 100
###begin p 101
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 131 138 131 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050094-t002">Table 2</xref>
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-st001">Table S1</xref>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 438 442 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 454 461 454 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050094-t001">Table 1</xref>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 588 590 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b033">33</xref>
###xml 712 716 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
It should also be noted that a major set of IFN-inducible genes (43 genes) were specifically down-regulated in the vegf 5'-tumors (Table 2), whereas none of IFN-inducible genes were included in the up-regulated genes (Table S1). Using quantitative RT-PCR, we compared mRNA levels of nine IFN-inducible genes between the vegf 5'-tumors and the vegf 5'mut-tumors, and validated significant down-regulation of eight out of nine genes in the vegf 5'-tumors (Table 1). An IFN-inducible gene stat1 encoding a critical transcription factor for both type I (alpha/beta) and type II (gamma) IFNs [33] was also significantly down-regulated, suggesting specific deactivation of the IFN/STAT1 pathway in the rapidly growing vegf 5'-tumors.
###end p 101
###begin p 102
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
List of IFN-Responsive Genes Selectively Down-Regulated in vegf 5'UTR-Overexpressing Cells
###end p 102
###begin title 103
STAT1 Expression and Responsiveness to IFNs
###end title 103
###begin p 104
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 289 297 289 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 386 391 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 463 467 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 479 487 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 578 582 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 592 600 584 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
To confirm that the vegf mRNA 5'UTR selectively deactivated the IFN-dependent pathway in vitro, we measured the levels of stat1 mRNA and its protein in each stable clone by quantitative RT-PCR and immunoblotting, respectively. Similar amounts of stat1 mRNA were observed among all clones (Figure 5A). Both HCT116/YFP and HCT116/vegf 5'mut cells responded to rhIFNalpha and up-regulated stat1 mRNA expression, but this up-regulation was not observed in the HCT116/vegf 5' clones (Figure 5A). Consistent with these, induction of STAT1 protein by IFNalpha was defect in the HCT116/vegf 5'cells (Figure 5B).
###end p 104
###begin title 105
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Impaired Responses to IFNs in the vegf 5'UTR-Expressing Clones
###end title 105
###begin p 106
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 239 244 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
###xml 336 341 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 363 364 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 462 463 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A and B) Repression of stat1 mRNA and its protein expression in the vegf 5'UTR-expressing cells. Total RNA or whole cell extracts were prepared from the indicated clones before and 24 h after treatment with 500 U/ml rhIFNalpha. Levels of stat1 mRNA were measured using quantitative RT-PCR (A). Values were normalized for the amount of gapdh mRNA (means +/- SEM, n = 4). Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05). Amounts of STAT1alpha (91 kDa) and STAT1beta (84 kDa) isoforms were measured by Western blot analysis using an anti-STAT1 Ab (B, upper panel). The levels of beta-actin are shown as a loading control (B, lower panel).
###end p 106
###begin p 107
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 670 671 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C and D) Suppression of IFN-mediated transactivation activities in the vegf 5'UTR-expressing cells. Each stable transfectant was transiently cotransfected with pTK-Renilla (as a monitor for transfection efficiency) and with a luciferase reporter plasmid containing ISRE sequence (C) or GAS sequence (D). Twenty-four hours after transfection, the cells were treated with 500 U/ml rhIFNalpha (C) or 500 U/ml rhIFNgamma (D) for 24 h. The luciferase activity of each construct was calculated as LucF/LucR activity. Results are expressed as fold changes compared to untreated cells. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 107
###begin p 108
###xml 43 47 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 311 312 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 409 410 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(E) Resistance to 5-FU and IFNalpha in the vegf 5'UTR-expressing cells. Stable transfectants were untreated or treated with 500 U/ml rhIFNalpha, 80 muM 5-FU, or 80 muM 5-FU plus 500 U/ml rhIFNalpha for 48 h. Percentages of apoptotic cells were calculated by the TUNEL-staining method. Values are means +/- SEM, n = 4. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 108
###begin p 109
###xml 43 47 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 174 175 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 272 273 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(F) Resistance to 5-FU and IFNgamma in the vegf 5'UTR-expressing cells. As in (E), but 500 U/ml rhIFNgamma was used instead of 500 U/ml rhIFNalpha. Values are means +/- SEM, n = 4. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 109
###begin p 110
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b034">34</xref>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 635 639 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 729 737 709 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 784 792 760 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 818 822 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 864 872 840 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 878 879 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">5</xref>
###xml 964 972 940 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg009">FigureS9</xref>
###xml 1264 1273 1217 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg009">Figure S9</xref>
STAT1 plays a crucial role in the expression of the majority of IFN-inducible genes [34]. We therefore tested whether the HCT116/vegf 5' cells actually showed decreased STAT1-dependent transcriptional activity. For this purpose, we used two different STAT1-dependent reporter plasmids encoding a promoter that either contained ISRE-binding sites (pISRE-Luc) that mainly respond to IFNalpha or GAS-binding sites (pGAS-Luc) that preferentially respond to IFNgamma. Each stable clone was transiently transfected with pISRE-Luc or pGAS-Luc reporter plasmid, and then they were treated with rhIFNalpha or rhIFNgamma for 24 h. In the HCT116/vegf 5' clones, there was significant impairment of the IFNalpha-stimulated response of ISRE (Figure 5C) and the IFNgamma-dependent response of GAS (Figure 5D) compared to the HCT116/vegf 5'mut clones or to the HCT116/YFP cells (Figure 5C and 5D). We confirmed that the IFN receptors were equally expressed in all clones tested (FigureS9A). These results suggest that the IFNalpha pathway might be more severely impaired than the IFNgamma pathway. We also measured the levels of endogenous IFNalpha, beta, and gamma mRNAs in each clone by quantitative RT-PCR. There was no difference in the level of IFNalpha mRNA in each clone (Figure S9B). Neither clone expressed detectable amounts of IFNbeta or IFNgamma mRNAs.
###end p 110
###begin p 111
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 205 213 205 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g006">Figure 6</xref>
###xml 229 237 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g006">Figure 6</xref>
###xml 615 623 607 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g006">Figure 6</xref>
We further examined the effects of stable knockdown of endogenous vegf mRNA on STAT1 expression in HCT116 cells (HCT116/siVEGF). Endogenous vegf mRNA was successfully silenced in the HCT116/siVEGF clones (Figure 6A). As shown in Figure 6B, the basal and the IFNalpha-stimulated expression levels of STAT1 were significantly increased in the HCT116/siVEGF clones compared with the control clone (HCT116/siControl) and parental cells (HCT116). Consistent with these results, both the basal and the IFNalpha-stimulated ISRE-dependent transcriptional activities were increased 2- to 3-fold in the HCT116/siVEGF clones (Figure 6C).
###end p 111
###begin title 112
###xml 68 72 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Enhancement of STAT1 Expression and IFNalpha Response in the Stable vegf Knockdown Cells
###end title 112
###begin p 113
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 144 145 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) Expression levels of vegf mRNA were measured using quantitative RT-PCR. Values were normalized for the amount of gapdh mRNA (means +/- SEM, n = 4).
###end p 113
###begin p 114
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
(B) Increased expression of STAT1 in the stable vegf knockdown cells. Total proteins were extracted from the indicated clones before and 24 h after treatment without or with 500 U/ml IFNalpha. Amounts of STAT1alpha and STAT1beta isoforms were measured by Western blot analysis using an anti-STAT1 Ab.
###end p 114
###begin p 115
###xml 76 80 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 189 196 185 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 384 391 376 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 504 505 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C) Enhancement of IFNalpha-mediated transactivation activity in the stable vegf knockdown cells. Each stable transfectant was transiently cotransfected with pISRE reporter plasmid and pTK-Renilla. Twenty-four hours after transfection, the cells were treated without or with 500 U/ml rhIFNalpha for 24 h. The luciferase activity of each construct was calculated as firefly luciferase/Renilla luciferase activity. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 115
###begin title 116
###xml 71 75 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Impairment of the IFNalpha-Dependent Anti-apoptotic Pathway in Growing vegf 5'-Tumors
###end title 116
###begin p 117
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b035">35</xref>
###xml 445 449 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 487 495 471 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">Figure 5</xref>
###xml 501 502 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g005">5</xref>
###xml 577 581 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
To assess whether the reduced IFN signals were responsible for the malignant transformation of the HCT116/vegf 5' cells, we examined the effect of IFNs on 5-FU-induced apoptosis, as IFNs are known to potentiate the pharmacological action of 5-FU [35]. Treatment with rhIFNalpha or rhIFNgamma alone did not induce apoptosis in any of the clones tested, while both IFNalpha and IFNgamma significantly enhanced 5-FU-induced apoptosis in the HCT116/vegf 5'mut cells or the HCT116/YFP cells (Figure 5E and 5F). In contrast, neither IFNalpha nor IFNgamma had an effect in the HCT116/vegf 5' cells.
###end p 117
###begin p 118
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 206 210 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 221 222 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 277 278 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 296 300 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 314 315 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 406 407 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 600 608 588 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g007">Figure 7</xref>
###xml 626 630 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 645 653 633 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g007">Figure 7</xref>
###xml 705 709 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 902 906 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1084 1092 1064 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g007">Figure 7</xref>
###xml 442 447 <span type="species:ncbi:10090">mouse</span>
Finally, we examined whether growing vegf 5'-tumors had impaired responses to IFNalpha in vivo. We therefore focused on the effects of rhIFNalpha on tumor growth. For these experiments, we implanted HCT116/vegf 5' (5 x 106 cells) in the left flank and either HCT116/YFP (1 x 107 cells) or HCT116/vegf 5'mut (1 x 107 cells) in the right flank of the same animal. When both tumors reached approximately 40 mm3 on day 7, we started to treat the mouse once a day with 5-FU (30 mg/kg body weight) or with a combination of 5-FU (30 mg/kg body weight) and rhIFNalpha (50,000 U). At day 4 in the YFP-tumors (Figure 7A) or day3 in the vegf 5'mut-tumors (Figure 7C) after the 5-FU treatment, the YFP-tumors and the vegf 5'mut-tumors began to reduce in size, respectively. Simultaneous treatment with rhIFNalpha accelerated this reduction and most tumors disappeared within 7 d. In contrast, the responses of the vegf 5'-tumors to 5-FU and rhIFNalpha were strikingly different. Treatment with 5-FU initially and transiently decreased tumor sizes, but they then began to grow rapidly from day 4 (Figure 7B). Simultaneous administration of rhIFNalpha did not have any effect on tumor growth.
###end p 118
###begin title 119
Effects of IFNalpha Treatment on Growth of Xenograft Tumors
###end title 119
###begin p 120
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 476 484 472 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g004">Figure 4</xref>
###xml 512 513 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 598 599 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 631 632 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 252 257 <span type="species:ncbi:10090">mouse</span>
An athymic nude mouse was implanted subcutaneously with the vegf 5'-G5 clone (5 x 106 cells) in the right flank (B) and the YFP-G11(A) or the vegf 5'mut-D5 clone (C) (1 x 107 cells) in the left flank. On day 7 when tumors had grown to be palpable, the mouse was intraperitoneally injected with 5-FU (30 mg/kg body weight), or 5-FU (30 mg/kg body weight) plus rhIFNalpha (50,000 U) once a day. Time-dependent changes in tumor masses were measured as described in the legend to Figure 4. Values are means +/- SEM, n = 4. #, Significantly different compared to 5-FU-treated tumors at each time point (p < 0.05 by two-tailed Student's t-test). A photograph showing a typical tumor growing on day 7 of IFN-treatment is inserted in each figure.
###end p 120
###begin title 121
Discussion
###end title 121
###begin p 122
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 157 160 157 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 182 185 182 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 244 247 244 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
In the present study, we show a novel function of the vegf 5'UTR in tumor cell survival and growth. Both treatment of vegf-knockdown HCT116 cells with rhVEGF165 and treatment of VEGF165-overexpressing HCT 116 cells with a neutralizing anti-VEGF165 Ab suggest the presence of vegf mRNA-mediated anti-apoptotic action against anti-cancer drugs (5-FU, etoposide, and doxorubicin). We determined that the anti-apoptotic action resided in a 270-nt-long element between positions nt 475 and nt 745 of the 5' UTR of vegf mRNA. The 5' UTR could exert the anti-apoptotic action even in the presence of a protein synthesis inhibitor. These results suggest that the 5'UTR may function as a regulatory RNA.
###end p 122
###begin p 123
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 656 659 656 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fas</italic>
###xml 661 666 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdcd1</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrg1</italic>
###xml 678 681 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bax</italic>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mia</italic>
###xml 799 803 799 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 912 917 912 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cxcl1</italic>
###xml 919 924 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cxcl2</italic>
###xml 926 931 926 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cxcr4</italic>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mia1</italic>
###xml 943 949 943 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-19</italic>
###xml 991 995 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 260 269 <span type="species:ncbi:10090">nude mice</span>
To further clarify the potential role of vegf 5'UTR RNA, we established HCT116/vegf 5' and HCT116/vegf 5'mut clones. HCT116/vegf 5' cells, but not HCT116/vegf 5'mut cells, showed anchorage-independent growth in vitro and rapidly grew when implanted in athymic nude mice, indicating that vegf mRNA 5'UTR facilitates tumor progression. The rapid growth observed in the vegf 5'-tumors might be due to the acquisition of resistance to apoptosis (the process that eliminates defective cells), which contributes to tumor development and resistance to drug therapy. Microarray and quantitative RT-PCR analyses demonstrated that expression of pro-apoptotic genes (fas, pdcd1, nrg1, and bax) and an anti-apoptotic gene (mia) was up-regulated and markedly down-regulated, respectively, in the rapidly growing vegf 5'-tumors. In addition, microarray analysis also showed that the expression of cell growth-promoting genes (cxcl1, cxcl2, cxcr4, mia1, and fgf-19) was up-regulated in the rapidly growing vegf 5'-tumors.
###end p 123
###begin p 124
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b036">36</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b037">37</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
The combination of both dysregulated cell proliferation and suppressed cell death are required for neoplastic progression [36]. In addition, survival and growth under anchorage-independent conditions are required for the progression [37]. This anchorage-independent property of tumor cells correlates with their in vivo oncogenic potential. Thus, we consider that the vegf 5'UTR may increase the ability not only to suppress apoptosis but also to survive and grow in an anchorage-independent manner, resulting in the acceleration of tumor formation.
###end p 124
###begin p 125
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stat1</italic>
The precise sequence and structure of the 5'UTR of vegf mRNA as well as the molecular target(s) that interact with the RNA remain to be elucidated. However, it seems likely that such a profound change in cell function induced by RNA would require a global change of gene expression in cells. Our results support this notion by showing that the vegf mRNA 5'UTR modulated expression of numerous genes. One of the striking findings is that many of the down-regulated genes belong to a set of IFN-inducible genes, including stat1.
###end p 125
###begin p 126
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b038">38</xref>
###xml 290 295 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 297 302 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 307 310 303 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 356 365 352 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg007">Figure S7</xref>
###xml 471 480 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg007">Figure S7</xref>
###xml 656 659 644 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bip</italic>
###xml 661 666 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 671 676 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-2</italic>
###xml 737 743 725 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdgf-b</italic>
###xml 778 787 766 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050094-sg007">Figure S7</xref>
###xml 884 888 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Since it is reported that IFN down-regulates IRES-dependent translation of distinct mRNAs [38], overexpression of the IRES-containing 5'UTR might attenuate the IFN signal, leading to the down-regulation of IFN-inducible genes. We therefore tested whether IFNalpha affected IRES activity of c-myc, fgf-2, or bip using a bicistronic luciferase assay system (Figure S7A) in our experimental conditions, and found that IFNalpha did not modify at least these IRES activities (Figure S7C). At the same time, we also confirmed that IFNalpha signaling, estimated using the ISRE-dependent transcription reporter assay, was not inhibited in the cells overexpressing bip, c-myc, or fgf-2 5'UTR, nor was it inhibited in the cells overexpressing the pdgf-b 5'UTR that have no IRES activity (Figure S7D). Although these results suggest that the suppression of IFN signaling may be specific for the vegf 5'UTR, further studies are needed to clarify the molecular mechanism for the suppression.
###end p 126
###begin p 127
###xml 219 221 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b039">39</xref>
###xml 472 474 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b040">40</xref>
###xml 652 654 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b041">41</xref>
###xml 787 789 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b042">42</xref>
###xml 790 792 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b043">43</xref>
###xml 820 824 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1121 1123 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b033">33</xref>
###xml 1166 1170 1154 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1182 1189 1170 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050094-t001">Table 1</xref>
###xml 1277 1281 1265 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1305 1309 1293 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1358 1366 1342 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050094-g007">Figure 7</xref>
###xml 72 76 <span type="species:ncbi:10090">Mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 235 240 <span type="species:ncbi:10090">mouse</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
The IFNs/STAT1 signal is one of the key pathways for tumor suppression. Mice with a targeted deletion of the STAT1 or IFNgamma receptor develop chemically induced or spontaneous tumors more rapidly than wild-type mice [39]. Similarly, mouse embryonic fibroblasts deficient in the IFNalpha receptor undergo spontaneous malignant transformation, and the IFNalpha receptor-deficient mice develop papillomas of the skin at a high rate when treated with a chemical carcinogen [40]. In contrast, the reconstitution of STAT1 suppressed the tumorigenicity of STAT1-deficient tumor cells in vivo, demonstrating that STAT1 acts as an important tumor suppressor [41]. Indeed, the majority of cancer cell lines and primary tumors are resistant to IFNs, often through inhibition of STAT1 expression [42,43]. We propose here that the vegf mRNA 5'UTR negatively regulates expression of STAT1, leading to suppression of STAT1-dependent transcriptional activities. It has been suggested that STAT1 directly regulates DNA damage-induced apoptosis by transcriptional activation of apoptosis modulating genes, such as TRAIL, Fas, and XAF-1 [33], all of which were down-regulated in the vegf 5'-tumors (Table 1). Thus, the suppression of STAT1 may be crucial for malignant transformation of HCT116/vegf 5' cells. In fact, the vegf 5'-tumors did not response to IFNalpha therapy (Figure 7).
###end p 127
###begin p 128
###xml 208 210 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b044">44</xref>
###xml 211 213 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b045">45</xref>
###xml 250 254 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 516 517 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b001">1</xref>
###xml 518 519 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b004">4</xref>
###xml 546 547 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b001">1</xref>
###xml 635 637 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b041">41</xref>
###xml 638 640 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b046">46</xref>
###xml 667 669 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b033">33</xref>
###xml 670 672 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b047">47</xref>
###xml 709 713 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 720 721 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b001">1</xref>
###xml 722 724 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b048">48</xref>
###xml 725 727 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b049">49</xref>
###xml 926 930 922 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Tumor cell growth and survival may require both expression of VEGF and down-regulation of the IFN pathway. Consistent with this notion, it is known that IFNalpha transcriptionally suppresses VEGF expression [44,45]. In contrast, we suggest here that vegf mRNA may negatively regulate the IFN signaling pathway by repressing STAT1. This reciprocal regulation of VEGF and STAT1 is entirely feasible as these two molecules exert opposing biological functions: VEGF promotes proliferation, metastasis, and angiogenesis [1-4], and inhibits apoptosis [1]; in contrast, STAT1 negatively regulates proliferation, metastasis, and angiogenesis [41,46], and promotes apoptosis [33,47]. Tumor cells abundantly expressing vegf mRNA [1,48,49] may use this negative regulatory mechanism to gain advantages of growth and survival to escape from the IFN-mediated anti-tumor machinery. Indeed, we found here that stable knockdown of endogenous vegf mRNA by siRNA increased STAT1 expression.
###end p 128
###begin p 129
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 549 553 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifn-</italic>
###xml 565 567 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b050">50</xref>
###xml 589 600 581 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tropomyosin</italic>
###xml 607 609 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b051">51</xref>
###xml 629 632 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tnf</italic>
###xml 645 647 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b052">52</xref>
###xml 711 713 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b053">53</xref>
###xml 776 780 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
At present, the precise mechanisms for the vegf 5'UTR-mediated anti-apoptotic action are still unknown. However, our preliminary experiments showed that the vegf 5'UTR RNA might interact with double-stranded RNA-activated protein kinase (PKR) protein in the cells expressing the full-length vegf mRNA or the vegf 5'UTR RNA, which were examined by the pull-down assay using an antisense oligonucleotide probe specific for the vegf 5'UTR sequence (unpublished data). It is reported that PKR binds several structured UTRs of mRNA, such as the 5'UTR of ifn-gamma mRNA [50], the 3'UTR of alpha-tropomyosin mRNA [51], and the 3'UTR of tnf-alpha mRNA [52]. PKR associates with tumor suppressor, such as IRF-1 and p53 [53] and induces apoptosis. Our preliminary data suggest that the vegf 5'UTR might interact with PKR and lead to suppression of PKR-mediated apoptotic pathway. However, this is still an unproven hypothesis, and further experiments are being carried out in our laboratory.
###end p 129
###begin p 130
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b017">17</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b018">18</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b054">54</xref>
###xml 453 464 449 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tropomyosin</italic>
###xml 586 588 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b018">18</xref>
###xml 604 628 600 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ribonucleotide reductase</italic>
###xml 692 702 688 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">prohibitin</italic>
###xml 858 860 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b019">19</xref>
###xml 861 863 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b020">20</xref>
###xml 902 907 898 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 1158 1160 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b021">21</xref>
###xml 1203 1207 1199 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 896 901 <span type="species:ncbi:9606">human</span>
###xml 960 965 <span type="species:ncbi:9606">human</span>
Recent studies have revealed that a large number of non-coding RNAs play a critical role in tumorigenesis [17]. Our findings support the concept originally put forward by Blau and colleagues [18,54] that non-coding regions of mRNAs can act as RNA regulators for tumor malignancy. There is increasing evidence that the UTR of certain mRNAs significantly suppresses the tumorigenic properties of cancer cells both in vitro and in vivo. The 3'UTR of alpha-tropomyosin mRNA suppresses the proliferation, invasion, and destruction of muscle tissues characteristic of rhabdomyosarcoma cells [18]. The 3'UTR of ribonucleotide reductase, a key rate-limiting enzyme in DNA synthesis, and the 3'UTR of prohibitin, an inhibitor of cell proliferation, significantly suppress the tumorigenic properties and metastatic phenotype of transformed fibroblasts and MCF7 cells [19,20]. In addition, the 5'UTR of the human c-myc P0 transcript suppresses the malignant phenotype of human breast cancer cells with decreased anchorage-independent proliferation, enhanced susceptibility to programmed cell death, and complete loss of the ability to form tumors in the intact animal [21]. To the best of our knowledge, the 5'UTR vegf mRNA is the first example of tumor-promoting UTR RNA.
###end p 130
###begin p 131
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b014">14</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b055">55</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b056">56</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b014">14</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b057">57</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b058">58</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050094-b059">59</xref>
###xml 950 954 950 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1100 1104 1100 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 1196 1200 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
VEGF protein is considered to be an important therapeutic target for cancer treatment, and anti-VEGF strategies are undergoing clinical evaluation [14]. A number of preclinical studies have demonstrated that anti-VEGF therapy alone can suppress the growth of established tumors [55,56]. Unlike these preclinical studies, anti-VEGF-specific Ab (bevacizumab) alone has not been shown to increase survival in lung and colorectal cancer patients [14]. The combined use of bevacizumab with standard chemotherapy increased overall survival in metastatic colorectal cancer [57], but did not improve the clinical outcome in metastatic breast cancers in previously treated patients [58]. Furthermore, the combination of the VEGF receptor tyrosine kinase inhibitor, vatalanib, with chemotherapy did not show an increased survival rate in metastatic colorectal cancer patients [59]. Our finding that the novel intrinsic tumor-promoting activity presents in the vegf mRNA might explain, at least in part, the inconsistencies of outcome associated with VEGF-VEGFR strategies. The present study suggests that both vegf mRNA and VEGF protein may synergistically promote the malignancy of tumor cells. Thus anti-vegf transcript therapy, such as siRNA-based gene silencing, in combination with anti-VEGF therapy might provide optimal anti-tumor effects, including inhibition of angiogenesis, blockade of tumor cell survival, and enhanced sensitivity to radiation and drug therapies.
###end p 131
###begin title 132
Supporting Information
###end title 132
###begin title 133
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effect of vegf Transcript on Susceptibility to Anti-cancer Drugs
###end title 133
###begin p 134
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 570 571 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A and B) Knockdown of vegf transcript increases apoptosis induced by etoposide and doxorubicin. Cells untransfected (-) or transfected with the indicated plasmids for 24 h were treated with 3 muM etoposide (A), 20 nM doxorubicin (B), or rhVEGF protein (1 or 2 ng/ml) combined with each drug for 40 h. Apoptosis was evaluated by calculating the percentages of TUNEL-positive cells. Values are means +/- standard error of the mean (SEM) from four independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 134
###begin p 135
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 452 453 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C and D) Overexpression of vegf transcript induces resistance to anti-cancer drugs. Cells untransfected (-) or transfected with the indicated constructs for 24 h were treated with 20 muM etoposide (C) or 340 nM doxorubicin (D) for 48 h, and then apoptosis was evaluated by the TUNEL method. Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 135
###begin p 136
(1.1 MB TIF)
###end p 136
###begin p 137
Click here for additional data file.
###end p 137
###begin title 138
Expression of Transfected Construct Transcripts and Their Proteins
###end title 138
###begin p 139
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 281 287 <span type="species:ncbi:9986">rabbit</span>
###xml 316 321 <span type="species:ncbi:10090">mouse</span>
(A) Levels of transfected vegf mRNAs and their proteins were measured by Northern and Western analyses, respectively. Northern hybridization of vegf mRNA was performed using a cDNA probe specific for vegf ORF. Levels of HA-tagged VEGF and beta-actin proteins were measured using a rabbit polyclonal anti-HA Ab and a mouse monoclonal Ab against beta-actin, respectively.
###end p 139
###begin p 140
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</italic>
###xml 124 127 <span type="species:ncbi:9685">cat</span>
###xml 196 202 <span type="species:ncbi:9986">rabbit</span>
(B) Levels of transfected vegf 5'UTR-CAT constructs were analyzed by Northern blot analysis using a cDNA probe specific for cat. Levels of L-VEGF protein were measured by Western blotting using a rabbit polyclonal anti-L-VEGF Ab.
###end p 140
###begin p 141
(1.8 MB TIF)
###end p 141
###begin p 142
Click here for additional data file.
###end p 142
###begin title 143
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effects of vegf 5'UTR on 5-FU-Induced Apoptosis
###end title 143
###begin p 144
###xml 237 238 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 335 336 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A-C) HCT116 cells transfected with the indicated plasmids for 24 h were treated with 80 muM 5-FU for 40 h. Cells undergoing apoptosis were detected by the TUNEL method (A and B) or the APOPercentage assay (C). Values are means +/- SEM, n = 4. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 144
###begin p 145
###xml 181 184 178 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 376 377 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 387 391 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 423 427 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 427 430 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 160 165 <span type="species:ncbi:10090">mouse</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
(D) Twenty-four hours after transfection with the indicated plasmids, the cells were treated with 80 muM of 5-FU or 80 muM 5-FU plus 5 mug/ml of the monoclonal mouse anti-human VEGF165-neutralizing Ab (+ Ab) for 24 h. Then, apoptosis was evaluated by the caspase 3/7 activity. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05). vegf mRNA wt, wild-type full-length vegf165 mRNA without mutation in sequence encoding signal peptide.
###end p 145
###begin p 146
(5.5 MB TIF)
###end p 146
###begin p 147
Click here for additional data file.
###end p 147
###begin title 148
Effects of Several 5'UTR RNAs on Resistance to 5-FU in HCT116 Cells
###end title 148
###begin p 149
###xml 168 169 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 266 267 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cells transfected with the indicated plasmid for 24 h were treated with 80 muM 5-FU for 40 h. Percentages of apoptotic cells were calculated. Values are means +/- SEM, n = 4. Means with different superscripts are significantly different by ANOVA and Scheffe's test (p < 0.05).
###end p 149
###begin p 150
(919 KB TIF)
###end p 150
###begin p 151
Click here for additional data file.
###end p 151
###begin title 152
Prediction of RNA Secondary Structures
###end title 152
###begin p 153
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
The sequences of vegf 5'UTR (A) and mutated vegf 5'UTR (B) were analyzed using the mfold algorithm 3.2 of Zuker.
###end p 153
###begin p 154
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
A circle shown in (A) indicates the stem-loop located in the region that is required for the vegf 5'UTR function.
###end p 154
###begin p 155
(2.6 MB TIF)
###end p 155
###begin p 156
Click here for additional data file.
###end p 156
###begin title 157
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effects of vegf 5'UTR RNA on Resistance to 5-FU in RKO, HEK293, and AGS Cells
###end title 157
###begin p 158
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr1</italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegfr2</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp1</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrp2</italic>
(A) The levels of mRNAs for VEGF receptors (vegfr1, vegfr2, nrp1, and nrp2) in the indicated cell lines were analyzed by RT-PCR.
###end p 158
###begin p 159
###xml 251 255 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 348 351 345 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 596 597 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 338 343 <span type="species:ncbi:9606">human</span>
(B-D) RKO cells (B), HEK293 cells (C), and AGS cells (D) were transfected with the indicated constructs for 24 h. The cells were untreated or treated with 150 muM 5-FU for 48 h. In the case of cells transfected with the plasmid expressing full-length vegf mRNA, the cells were treated with 150 muM 5-FU plus 5 mug/ml of a monoclonal anti-human VEGF165-neutralizing Ab (+ Ab) for 48 h. Then, apoptosis was evaluated by the TUNEL method. Values are means +/- SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe's test (p < 0.05).
###end p 159
###begin p 160
(1.4 MB TIF)
###end p 160
###begin p 161
Click here for additional data file.
###end p 161
###begin title 162
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Effect of the vegf 5'UTR RNA or IFNalpha on Cellular IRES Activities
###end title 162
###begin p 163
(A) Schematic diagram of bicistronic plasmid. The bicistronic cassette expresses the LucR in a cap-dependent manner and LucF in an IRES-dependent manner. Each IRES or hairpin control is located between the two cistrons.
###end p 163
###begin p 164
###xml 66 70 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
(B) HCT116 cells were cotransfected with 0.5 mug of the indicated vegf 5'UTR-expressing plasmid and 0.25 mug of bicistronic plasmid containing the indicated 5'UTR. The each IRES activity was calculated as LucF/LucR activity.
###end p 164
###begin p 165
(C) IFNalpha has no effect on cellular IRES activity. HCT116 cells were transfected with the indicated bicistronic plasmid for 24 h, then they were treated with 500 U/ml IFNalpha for 24 h. The luciferase activity of each construct was calculated as described in (B).
###end p 165
###begin p 166
(D) Overexpression of IRES-containing 5'UTR has no effect on IFNalpha signaling. HCT116 cells were cotransfected with the indicated 5'UTR-CAT-expressing plasmid and luciferase reporter plasmid containing ISRE sequence. Twenty-four hours after transfection, the cells were treated with 500 U/ml rhIFNalpha for 24 h. The luciferase activity of each construct was measured and calculated as LucF/LucR activity.
###end p 166
###begin p 167
(994 KB TIF)
###end p 167
###begin p 168
Click here for additional data file.
###end p 168
###begin title 169
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
Expression Levels of Transfected mRNA and Endogenous vegf mRNA, and Secretion Levels of VEGF by Stable Transfectants
###end title 169
###begin p 170
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yfp</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yfp</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
(A) Levels of exogenous vegf 5' UTR-yfp mRNA (upper panel), endogenous vegf mRNA (middle panel), and gapdh mRNA (loading control, lower panel) were measured by Northern hybridization using probes specific for yfp, vegf ORF, and gapdh, respectively. The transfectants expressed similar levels of chimeric RNA. The stable transfections of different chimeric mRNAs did not significantly changes the expression of endogenous vegf mRNA.
###end p 170
###begin p 171
###xml 19 22 19 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 121 122 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(B) Amounts of VEGF165 secreted into the culture medium for 24 h were measured by ELISA assay. Values are means +/- SEM, n = 4.
###end p 171
###begin p 172
(1.5 MB TIF)
###end p 172
###begin p 173
Click here for additional data file.
###end p 173
###begin title 174
Expression of IFN Receptors and IFN-alpha2 mRNAs in Stable Clones
###end title 174
###begin p 175
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar1</italic>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnar2</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr1</italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifngr2</italic>
###xml 192 196 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifnr</italic>
(A) The mRNA levels of IFN receptors (ifnar1, ifnar2, ifngr1, and ifngr2) and beta-actin in the transfectants were measured by RT-PCR. Each stable clone showed similar levels of expression of ifnr mRNAs.
###end p 175
###begin p 176
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ifna2</italic>
(B) The levels of ifna2 mRNA in each clone were measured by quantitative RT-PCR.
###end p 176
###begin p 177
(1.6 MB TIF)
###end p 177
###begin p 178
Click here for additional data file.
###end p 178
###begin title 179
Confirmation of the Specificity of Antibody Reactivity
###end title 179
###begin p 180
Cell extracts were prepared from HCT116 cells treated with 500 U/ml IFN-alpha (A), or transfected with plasmid expressing L-VEGF (B), or HA-tagged VEGF (C). After each extract was either untreated (-) or treated (+) with antigen peptide, as described in the Methods section, they were subjected to Western blotting.
###end p 180
###begin p 181
(1.1 MB TIF)
###end p 181
###begin p 182
Click here for additional data file.
###end p 182
###begin title 183
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
List of All Genes Selectively Up-regulated in vegf 5'UTR-Expressing Tumors
###end title 183
###begin p 184
(462 KB DOC)
###end p 184
###begin p 185
Click here for additional data file.
###end p 185
###begin title 186
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf</italic>
List of All Genes Selectively Down-regulated in vegf 5'UTR-Expressing Tumors
###end title 186
###begin p 187
(365 KB DOC)
###end p 187
###begin p 188
Click here for additional data file.
###end p 188
###begin title 189
Accession Numbers
###end title 189
###begin p 190
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf-a</italic>
###xml 97 100 97 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mia</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl6</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">egfr</italic>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nrg1</italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdcd1</italic>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fas</italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bax</italic>
The GenBank () accession numbers of the genes discussed in this paper are vegf-a (NM_001025368), mia (NM_006533), bcl6 (NM_138931), egfr (X00588), nrg1 (NM_013962), pdcd1 (NM_005018), fas (NM_000043), and bax (NM_138764).
###end p 190
###begin p 191
The Gene Expression Omnibus (GEO) () raw chip data files discussed in this paper are accession number GSE8888.
###end p 191
###begin p 192
We thank Dr. Herve Prats and Dr. Anne-Catherine Prats (INSERM U858, France) for providing polyclonal anti-L-VEGF Ab and plasmids (p165mSPHA3', p165mSPHA, pVC, pSCT-CAT, pFGF2-CAT, pMycP2-CAT, pBip-CAT, pPDGFb-CAT, pRFL, pRMy2L, and pRBL).
###end p 192
###begin title 193
Abbreviations
###end title 193
###begin p 194
chloramphenicol acetyltransferase
###end p 194
###begin p 195
cycloheximide
###end p 195
###begin p 196
5-fluorouracil
###end p 196
###begin p 197
IFN-gamma-activated sequence
###end p 197
###begin p 198
interferon
###end p 198
###begin p 199
IFN-stimulated regulatory element
###end p 199
###begin p 200
nucleotide
###end p 200
###begin p 201
RNA-activated protein kinase
###end p 201
###begin p 202
###xml 12 17 <span type="species:ncbi:9606">human</span>
recombinant human
###end p 202
###begin p 203
real-time PCR
###end p 203
###begin p 204
standard error of the mean
###end p 204
###begin p 205
small-interfering RNA
###end p 205
###begin p 206
signal transducers and activators of transcription
###end p 206
###begin p 207
untranslated region
###end p 207
###begin p 208
vascular endothelial growth factor-A
###end p 208
###begin p 209
vascular endothelial growth factor receptor
###end p 209
###begin p 210
yellow fluorescent protein
###end p 210
###begin p 211
antibody
###end p 211
###begin title 212
References
###end title 212
###begin article-title 213
The biology of vascular endothelial growth factor
###end article-title 213
###begin article-title 214
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
###end article-title 214
###begin article-title 215
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
###end article-title 215
###begin article-title 216
Tumorigenesis and the angiogenic switch
###end article-title 216
###begin article-title 217
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
###end article-title 217
###begin article-title 218
Markedly elevated levels of vascular endothelial growth factor in malignant ascites
###end article-title 218
###begin article-title 219
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy
###end article-title 219
###begin article-title 220
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer
###end article-title 220
###begin article-title 221
Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade
###end article-title 221
###begin article-title 222
###xml 139 144 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy
###end article-title 222
###begin article-title 223
Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer
###end article-title 223
###begin article-title 224
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
###end article-title 224
###begin article-title 225
Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)
###end article-title 225
###begin article-title 226
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
###end article-title 226
###begin article-title 227
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer
###end article-title 227
###begin article-title 228
###xml 67 72 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1
###end article-title 228
###begin article-title 229
Non-coding RNAs: new players in eukaryotic biology
###end article-title 229
###begin article-title 230
Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin
###end article-title 230
###begin article-title 231
###xml 70 75 <span type="species:ncbi:9606">human</span>
Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer
###end article-title 231
###begin article-title 232
Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs
###end article-title 232
###begin article-title 233
###xml 63 68 <span type="species:ncbi:9606">human</span>
Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript
###end article-title 233
###begin article-title 234
Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA
###end article-title 234
###begin article-title 235
Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription
###end article-title 235
###begin article-title 236
New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation
###end article-title 236
###begin article-title 237
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site
###end article-title 237
###begin article-title 238
Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences
###end article-title 238
###begin article-title 239
Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs
###end article-title 239
###begin article-title 240
Mfold web server for nucleic acid folding and hybridization prediction
###end article-title 240
###begin article-title 241
Role of nicotinamide adenine dinucleotide phosphate oxidase 1 in oxidative burst response to Toll-like receptor 5 signaling in large intestinal epithelial cells
###end article-title 241
###begin article-title 242
Searching for IRES
###end article-title 242
###begin article-title 243
Tight control of platelet-derived growth factor B/c-sis expression by interplay between the 5'-untranslated region sequence and the major upstream promoter
###end article-title 243
###begin article-title 244
Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis
###end article-title 244
###begin article-title 245
The role of STATs in apoptosis
###end article-title 245
###begin article-title 246
How cells respond to interferons
###end article-title 246
###begin article-title 247
###xml 103 108 <span type="species:ncbi:9606">human</span>
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review
###end article-title 247
###begin article-title 248
Proliferation, cell cycle and apoptosis in cancer
###end article-title 248
###begin article-title 249
Molecular signaling regulating anchorage-independent growth of cancer cells
###end article-title 249
###begin article-title 250
Translational control of the interferon regulatory factor 2 mRNA by IRES element
###end article-title 250
###begin article-title 251
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Demonstration of an interferon gamma -dependent tumor surveillance system in immunocompetent mice
###end article-title 251
###begin article-title 252
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence
###end article-title 252
###begin article-title 253
Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells
###end article-title 253
###begin article-title 254
###xml 21 26 <span type="species:ncbi:9606">human</span>
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma
###end article-title 254
###begin article-title 255
Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line
###end article-title 255
###begin article-title 256
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis
###end article-title 256
###begin article-title 257
Interferon-alpha: regulatory effects on cell cycle and angiogenesis
###end article-title 257
###begin article-title 258
Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis
###end article-title 258
###begin article-title 259
STAT1-induced apoptosis is mediated by Caspases 2, 3, and 7
###end article-title 259
###begin article-title 260
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma
###end article-title 260
###begin article-title 261
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
###end article-title 261
###begin article-title 262
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR
###end article-title 262
###begin article-title 263
###xml 139 144 <span type="species:ncbi:9606">human</span>
In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3' untranslated regions of human alpha -tropomyosin
###end article-title 263
###begin article-title 264
###xml 54 59 <span type="species:ncbi:9606">human</span>
A cis-acting element in the 3'-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR
###end article-title 264
###begin article-title 265
Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action
###end article-title 265
###begin article-title 266
Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation
###end article-title 266
###begin article-title 267
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
###end article-title 267
###begin article-title 268
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
###end article-title 268
###begin article-title 269
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
###end article-title 269
###begin article-title 270
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
###end article-title 270
###begin article-title 271
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer
###end article-title 271
###begin p 272
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. KM, ST-K, and KR designed the research. KM, ST-K, MM, NY, YN, KN, and TK performed the research. KM and ST-K analyzed the data. KM, ST-K, and KR wrote the paper. KM, ST-K, MM, NY, YN, KN, TK, and KR discussed the results and commented on the manuscript.
###end p 272
###begin p 273
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported in part by grants from Grants-in-Aid for Scientific Research C (16590598) and Grants-in-Aid for Exploratory (19659187) from Japan Society for the Promotion of Science (JSPS) and Grants-in-Aid for Young Scientists A (18689018) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to ST-K), and from Grants-in-Aid for Scientific Research B (17390218) from the JSPS (to KR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 273
###begin p 274
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 274

